Commentary| Volume 8, ISSUE 3, P233-234, March 2023

Download started.


Using Multivariate Neurofunctional Signatures to Dissect the Specific Mental Processes Modulated by Novel Pharmacological Targets

      At a time when the pharmaceutical industry has reduced investment in the discovery of new psychotropic medications, Zhang et al. (
      • Zhang R.
      • Zhao W.
      • Qi Z.
      • Xu T.
      • Zhou F.
      • Becker B.
      Angiotensin II regulates the neural expression of subjective fear in humans: A precision pharmaco-neuroimaging approach.
      ) show how new approaches based on advances in brain imaging analysis methods can facilitate drug discovery. Specifically, they identify the angiotensin II type 1 receptor (AT1R) pathway as a promising novel target for the modulation of subjective fear experience in humans.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Zhang R.
        • Zhao W.
        • Qi Z.
        • Xu T.
        • Zhou F.
        • Becker B.
        Angiotensin II regulates the neural expression of subjective fear in humans: A precision pharmaco-neuroimaging approach.
        Biol Psychiatry Cogn Neurosci Neuroimaging. 2023; 8: 262-270
        • Kesselheim A.S.
        • Hwang T.J.
        • Franklin J.M.
        Two decades of new drug development for central nervous system disorders.
        Nat Rev Drug Discov. 2015; 14: 815-816
        • Lago T.R.
        • Brownstein M.J.
        • Page E.
        • Beydler E.
        • Manbeck A.
        • Beale A.
        • et al.
        The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.
        Psychopharmacology. 2021; 238: 2393-2403
        • Sartori S.B.
        • Singewald N.
        Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders.
        Pharmacol Ther. 2019; 204107402
        • LeDoux J.E.
        • Pine D.S.
        Using neuroscience to help understand fear and anxiety: A two-system framework.
        Am J Psychiatry. 2016; 173: 1083-1093
        • Barrett L.F.
        Are emotions natural kinds?.
        Perspect Psychol Sci. 2006; 1: 28-58
        • Marvar P.J.
        • Andero R.
        • Hurlemann R.
        • Lago T.R.
        • Zelikowsky M.
        • Dabrowska J.
        Limbic neuropeptidergic modulators of emotion and their therapeutic potential for anxiety and post-traumatic stress disorder.
        J Neurosci. 2021; 41: 901-910
        • Zhou F.
        • Zhao W.
        • Qi Z.
        • Geng Y.
        • Yao S.
        • Kendrick K.M.
        • et al.
        A distributed fMRI-based signature for the subjective experience of fear.
        Nat Commun. 2021; 12: 6643

      Linked Article

      • Angiotensin II Regulates the Neural Expression of Subjective Fear in Humans: A Precision Pharmaco-Neuroimaging Approach
        Biological Psychiatry: Cognitive Neuroscience and NeuroimagingVol. 8Issue 3
        • Preview
          Rodent models and pharmacological neuroimaging studies in humans have been used to test novel pharmacological agents to reduce fear. However, these strategies are limited with respect to determining process-specific effects on the actual subjective experience of fear, which represents the key symptom that motivates patients to seek treatment. In this study, we used a novel precision pharmacological functional magnetic resonance imaging approach based on process-specific neuroaffective signatures to determine effects of the selective angiotensin II type 1 receptor (AT1R) antagonist losartan on the subjective experience of fear.
        • Full-Text
        • PDF